Mucosal immunotherapy of tuberculosis: is there a value in passive IgA? (Q36410732)

14 August 2017

1 reference

title

Mucosal immunotherapy of tuberculosis: is there a value in passive IgA? (English)

1 reference

14 August 2017

0 references

1 reference

Rajko Reljic

1

1 reference

14 August 2017

Ann Williams

series ordinal

2

1 reference

14 August 2017

Juraj Ivanyi

series ordinal

3

1 reference

14 August 2017

publication date

28 February 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

86

1 reference

14 August 2017

issue

3-4

1 reference

14 August 2017

page(s)

179-190

1 reference

Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Immunotherapy of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

The effect of glucosaminylmuramyl dipeptide injection to mice on the course of tuberculous infection and in vitro superoxide anion production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Therapy of tuberculosis in mice by DNA vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Enhancement of immunocompetence in tuberculosis by DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

No beneficial effect of interferon-gamma treatment in 2 human immunodeficiency virus-infected patients with Mycobacterium avium complex infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Variable outcome of experimental interferon-? therapy of disseminated Bacillus Calmette-Guerin infection in two unrelated interleukin-12R?1-deficient Slovakian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Advances in antibody-mediated immunity againstMycobacterium tuberculosis: implications for a novel vaccine strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Intracellular antibody neutralizes Listeria growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Outer membrane protein-specific monoclonal antibodies protect SCID mice from fatal infection by the obligate intracellular bacterial pathogen Ehrlichia chaffeensis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Interaction of antigens and antibodies at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

IgA and the IgA Fc receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

The structure and function of human IgA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

A mucosal IgA-mediated excretory immune system in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Expression, purification and biochemical characterization of recombinant murine secretory component: a novel tool in mucosal immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

IgA interaction with the asialoglycoprotein receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Fc alpha/mu receptor mediates endocytosis of IgM-coated microbes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Mouse monoclonal IgA binds to the galectin-3/Mac-2 lectin from mouse macrophage cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Intracellular neutralization of virus by immunoglobulin A antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Inhibition of Bacterial Adherence by Secretory Immunoglobulin A: A Mechanism of Antigen Disposal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Protective efficacy of IgA monoclonal antibodies to O and H antigens in a mouse model of intranasal challenge with Salmonella enterica serotype Enteritidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Monoclonal IgA antibodies protect against Acanthamoeba keratitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Transmission of IgA and IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Differential potentiation of anti-mycobacterial activity and reactive nitrogen intermediate-producing ability of murine peritoneal macrophages activated by interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Mouse IgA inhibits cell growth by stimulating tumor necrosis factor-alpha production and apoptosis of macrophage cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Intracellular functions of galectins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Association of a macrophage galactoside-binding protein with Mycobacterium-containing phagosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Human galectin-3 is a novel chemoattractant for monocytes and macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Control of Mac-2 surface expression on murine macrophage cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Interaction between galectin-3 and FcgammaRII induces down-regulation of IL-5 gene: implication of the promoter sequence IL-5REIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Human keratinocytes release the endogenous beta-galactoside-binding soluble lectin immunoglobulin E (IgE-binding protein) which binds to Langerhans cells where it modulates their binding capacity for IgE glycoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Epsilon BP, a beta-galactoside-binding animal lectin, recognizes IgE receptor (Fc epsilon RI) and activates mast cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Lipoarabinomannan-reactive human secretory immunoglobulin A responses induced by mucosal bacille Calmette-Guérin vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Mac-1 (CD11b/CD18) as accessory molecule for Fc alpha R (CD89) binding of IgA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Interactions of galactosyltransferase with serum and secretory immunoglobulins and their component chains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Human intestinal epithelial cells express a novel receptor for IgA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

Immunoglobulin A monoclonal antibodies protect against Sendai virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

7 January 2021

Inhibition of Streptococcus mutans adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A (S-IgA) antibodies to cell surface protein antigen I/II: reversal by IgA1 protease cleavage

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

7 January 2021

Secretory immunoglobulin A and G antibodies prevent adhesion of Escherichia coli to human urinary tract epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

7 January 2021

Reactivation of latent tuberculosis: variations on the Cornell murine model

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

7 January 2021

Receptor-mediated binding and uptake of immunoglobulin A by human liver

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2006.01.011

7 January 2021

10.1016/J.TUBE.2006.01.011

Identifiers

DOI

1 reference

14 August 2017

1 reference